These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 36041258)

  • 41. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors.
    Snyder LA; Damle R; Patel S; Bohrer J; Fiorella A; Driscoll J; Hawkins R; Stratton CF; Manning CD; Tatikola K; Tryputsen V; Packman K; Mamidi RNVS
    Mol Cancer Ther; 2022 Jul; 21(7):1115-1124. PubMed ID: 35499386
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Difluoromethylornithine (DFMO) Enhances the Cytotoxicity of PARP Inhibition in Ovarian Cancer Cells.
    El Naggar O; Doyle B; Mariner K; Gilmour SK
    Med Sci (Basel); 2022 May; 10(2):. PubMed ID: 35736348
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
    Sulai NH; Tan AR
    Clin Adv Hematol Oncol; 2018 Jul; 16(7):491-501. PubMed ID: 30067621
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trapping Poly(ADP-Ribose) Polymerase.
    Shen Y; Aoyagi-Scharber M; Wang B
    J Pharmacol Exp Ther; 2015 Jun; 353(3):446-57. PubMed ID: 25758918
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cancer therapy by PARP inhibitors].
    Seimiya H
    Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.
    Pommier Y; O'Connor MJ; de Bono J
    Sci Transl Med; 2016 Oct; 8(362):362ps17. PubMed ID: 27797957
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Research progress on the association between environmental pollutants and the resistance mechanism of PARP inhibitors in ovarian cancer.
    Zhou L; Xiang J; He Y
    Environ Sci Pollut Res Int; 2021 Sep; 28(36):49491-49506. PubMed ID: 34370190
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
    O'Sullivan Coyne G; Chen AP; Meehan R; Doroshow JH
    Drugs; 2017 Feb; 77(2):113-130. PubMed ID: 28078645
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
    Cook SA; Tinker AV
    BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials.
    Nambiar DK; Mishra D; Singh RP
    Oncol Res; 2023; 31(4):405-421. PubMed ID: 37415740
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials.
    Liu Y; Meng J; Wang G
    Drug Des Devel Ther; 2018; 12():3013-3019. PubMed ID: 30271116
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship.
    Das PK; Matada GSP; Pal R; Maji L; Dhiwar PS; Manjushree BV; Viji MP
    Eur J Med Chem; 2024 Aug; 274():116535. PubMed ID: 38838546
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review.
    Buege M; Mahajan PB
    Rev Recent Clin Trials; 2015; 10(4):326-39. PubMed ID: 26374559
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies.
    Bahena-González A; Toledo-Leyva A; Gallardo-Rincón D
    Chin Clin Oncol; 2020 Aug; 9(4):51. PubMed ID: 32819110
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PARP inhibitors in prostate cancer: time to narrow patient selection?
    Markowski MC; Antonarakis ES
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):523-526. PubMed ID: 32521178
    [No Abstract]   [Full Text] [Related]  

  • 59. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
    Mirza MR; Pignata S; Ledermann JA
    Ann Oncol; 2018 Jun; 29(6):1366-1376. PubMed ID: 29750420
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PARP Inhibitors in Breast Cancer: a Short Communication.
    Daly GR; AlRawashdeh MM; McGrath J; Dowling GP; Cox L; Naidoo S; Vareslija D; Hill ADK; Young L
    Curr Oncol Rep; 2024 Feb; 26(2):103-113. PubMed ID: 38236558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.